Hareth Nahi

Publications
CV
Public outreach and news

Articles

Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2025;114(5):883-889
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes
Perrot A; Facon T; Plesner T; Usmani SZ; Kumar S; Bahlis NJ; Hulin C; Orlowski RZ; Nahi H; Mollee P; Ramasamy K; Roussel M; Jaccard A; Delforge M; Karlin L; Arnulf B; Chari A; Wang G; Gupta-Werner N; Kaila S; Pei H; Matt K; Gries KS; Carson R; Borgsten F; Weisel K
Article: LEUKEMIA. 2025;39(3):710-719
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study
Moreau P; Facon T; Usmani SZ; Bahlis N; Raje N; Plesner T; Orlowski RZ; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Tiab M; Macro M; Frenzel L; Leleu X; Wang G; Pei H; Krevvata M; Carson R; Borgsten F; Kumar SK
Article: CANCER MEDICINE. 2024;13(8):e7048
Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden
Uttervall K; Taetting L; Lemonakis K; Majd M; Crafoord J; Olsson M; Mellqvist U-H; Hansson M; Nahi H
Article: CANCERS. 2024;16(5):1024
Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group
Partanen A; Waage A; Peceliunas V; Schjesvold F; Anttila P; Saeily M; Uttervall K; Putkonen M; Carlson K; Haukas E; Sankelo M; Szatkowski D; Hansson M; Marttila A; Svensson R; Axelsson P; Lauri B; Mikkola M; Karlsson C; Abelsson J; Ahlstrand E; Sikioe A; Klimkowska M; Matuzeviciene R; Fenstad MH; Ilveskero S; Pelliniemi T-T; Nahi H; Silvennoinen R
Article: CANCER MEDICINE. 2023;12(22):20736-20744
Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
Nahi H; Afram G; Uttervall K; Lockmer S; Tatting L; Gahrton G; Kashif M; Alici E; Stromberg O; Klimkowska M; Lund J
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2023;72(5):1153-1167
Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy
Susek KH; Schwietzer YA; Karvouni M; Gilljam M; Keszei M; Hussain A; Lund J; Kashif M; Lundqvist A; Ljunggren H-G; Nahi H; Wagner AK; Alici E
Article: FUTURE ONCOLOGY. 2023;19(12):811-818
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Moreau P; van de Donk NWCJ; Nahi H; Oriol A; Nooka AK; Martin T; Rosinol L; Karlin L; Benboubker L; Mateos M-V; Popat R; Martinez-Lopez J; Sidana S; Delforge M; Pei L; Trancucci D; Olyslager Y; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Kobos R; Usmani SZ
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(8):1590-1599
Overall Survival With Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX): A Randomized, Open-Label, Phase III Trial
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Suzuki K; Plesner T; Yoon S-S; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Ahmadi T; Qin X; Mayo WG; Gai X; Carey J; Carson R; Moreau P
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;109(6):749-754
Conditioning with melphalan 200 mg/m² and subsequent ASCT improves progression-free and overall survival in elderly myeloma patients compared to standard of care
Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
Article: CANCER REPORTS. 2022;5(11):e1614
Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study
Walinder G; Genell A; Juliusson G; Svensson R; Santamaria AI; Crafoord J; Carlson K; Knut-Bojanowska D; Veskovski L; Lauri B; Lund J; Turesson I; Hansson M; Blimark CH; Nahi H
Article: HAEMATOLOGICA. 2022;107(10):2408-2417
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma
Usmani SZ; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis NJ; Flogegard M; Blade J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Lantz K; O'Rourke L; Heuck C; Delioukina M; Qin X; Nnane I; Qi M; Mateos M-V
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2022;387(6):495-505
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos M-V; Bahlis N; Popat R; Besemer B; Martinez-Lopez J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2022;28(5):258.e1-258.e8
Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment
Reinoso-Segura M; Caballero-Velazquez T; Herrera P; Patriarca F; Fanin R; Bruno B; Einsele H; Nahi H; Granell M; Lopez-Corral L; Reguera JL; Garcia-Cadenas I; Gahrton G; Perez-Simon JA
Article: LEUKEMIA. 2022;36(4):1066-1077
Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon T; Cook G; Usmani SZ; Hulin C; Kumar S; Plesner T; Touzeau C; Bahlis NJ; Basu S; Nahi H; Goldschmidt H; Quach H; Mohty M; Venner CP; Weisel K; Raje N; Hebraud B; Belhadj-Merzoug K; Benboubker L; Decaux O; Manier S; Caillot D; Ukropec J; Pei H; Van Rampelbergh R; Uhlar CM; Kobos R; Zweegman S
Article: CELL REPORTS MEDICINE. 2022;3(2):100508
Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma
Nahi H; Chrobok M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Blomberg P; Holmqvist P-H; Walther-Jallow L; Mellstrom K; Liwing J; Gustafsson C; Mansson R; Klimkowska M; Gahrton G; Lund J; Ljungman P; Ljunggren H-G; Alici E
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2022;108(1):34-44
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
Gregersen H; Peceliunas V; Remes K; Schjesvold F; Abildgaard N; Nahi H; Andersen NF; Vangsted AJ; Klausen TW; Helleberg C; Carlson K; Frolund UC; Axelsson P; Stromberg O; Blimark CH; Crafoord J; Tsykunova G; Eshoj HR; Waage A; Hansson M; Gulbrandsen N
Article: LANCET ONCOLOGY. 2021;22(11):1582-1596
Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Article: LANCET. 2021;398(10301):665-674
Teclistamab, a B-cell maturation antigenxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study
Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos M-V; Krishnan A
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(8):925-933
Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14)
Nahi H; Kashif M; Klimkowska M; Karvouni M; Wallblom A; Gran C; Hauenstein J; Frengen N; Gustafsson C; Afram G; Uttervall K; Lund J; Mansson R; Wagner AK; Alici E
Article: LEUKEMIA & LYMPHOMA. 2021;62(9):2227-2234
Involved free light chain: an early independent predictor of response and progression in multiple myeloma
Gran C; Afram G; Liwing J; Verhoek A; Nahi H
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2021;385(1):46-58
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Kastritis E; Palladini G; Minnema MC; Wechalekar AD; Jaccard A; Lee HC; Sanchorawala V; Gibbs S; Mollee P; Venner CP; Lu J; Schonland S; Gatt ME; Suzuki K; Kim K; Cibeira MT; Beksac M; Libby E; Valent J; Hungria V; Wong SW; Rosenzweig M; Bumma N; Huart A; Dimopoulos MA; Bhutani D; Waxman AJ; Goodman SA; Zonder JA; Lam S; Song K; Hansen T; Manier S; Roeloffzen W; Jamroziak K; Kwok F; Shimazaki C; Kim J-S; Crusoe E; Ahmadi T; Tran NP; Qin X; Vasey SY; Tromp B; Schecter JM; Weiss BM; Zhuang SH; Vermeulen J; Merlini G; Comenzo RL
Article: HAEMATOLOGICA. 2021;106(6):1725-1732
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
San-Miguel J; Usmani SZ; Mateos M-V; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson T; Clemens PL; Luo M; Farnsworth A; Nahi H; Chari A
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2021;61(5):614-627
Exposure-Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients
Luo MM; Usmani SZ; Mateos M-V; Nahi H; Chari A; San-Miguel J; Touzeau C; Suzuki K; Kaiser M; Carson R; Heuck C; Qi M; Zhou H; Sun Y-N; Parasrampuria DA
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2021;106(4):546-554
Improved survival in multiple Myeloma patients undergoing autologous stem cell transplantation is entirely in the standard cytogenetic risk groups
Afram G; Susek KH; Uttervall K; Wersall JD; Wagner AK; Luong V; Lund J; Gahrton G; Alici E; Nahi H
Article: ANNALS OF HEMATOLOGY. 2021;100(4):1065-1077
Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study
Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos M-V; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
Article: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2021;147(2):619-631
Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results
Usmani SZ; Mateos M-V; Hungria V; Iida S; Bahlis NJ; Nahi H; Magen H; Cavo M; Hulin C; White D; De Stefano V; Fastenau J; Slavcev M; Heuck C; Qin X; Pei H; Masterson T; Lantz K; Gries KS
Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(3):227-237
Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial
Perrot A; Facon T; Plesner T; Usmani SZ; Kumar S; Bahlis NJ; Hulin C; Orlowski RZ; Nahi H; Mollee P; Ramasamy K; Roussel M; Jaccard A; Delforge M; Karlin L; Arnulf B; Chari A; He J; Ho KF; Van Rampelbergh R; Uhlar CM; Wang J; Kobos R; Gries KS; Fastenau J; Weisel K
Article: ACTA HAEMATOLOGICA. 2021;144(5):519-527
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden
Nahi H; Walinder G; Patel V; Qu Y; Levine A; Majer I; Kutikova L; Hellqvist Franck E; Svensson MK; Hansson M
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(1):23-30
Comparative evaluation of involved free light chain and monoclonal spike as markers for progression from monoclonal gammopathy of undetermined significance to multiple myeloma
Gran C; Liwing J; Wagner AK; Verhoek A; Gezin A; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2020;105(6):751-754
Outcome of COVID-19 in multiple myeloma patients in relation to treatment
Susek KH; Gran C; Ljunggren H-G; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2020;105(2):196-202
Impact of performance status on overall survival in patients with relapsed and/or refractory multiple myeloma: Real-life outcomes of daratumumab treatment
Afram G; Gran C; Borg Bruchfeld J; Wagner AK; Hussain A; Alici E; Nahi H
Article: LANCET HAEMATOLOGY. 2020;7(6):e447-e455
Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2020;104(5):376-382
Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry
Walinder G; Samuelsson J; Nasman P; Hansson M; Juliusson G; Forsberg K; Svensson R; Linder O; Carlson K; Kristinsson SY; Mellqvist UH; Blimark CH; Turesson I; Nahi H
Article: LANCET HAEMATOLOGY. 2020;7(5):e370-e380
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial
Mateos M-V; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Blade J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
Article: BONE MARROW TRANSPLANTATION. 2020;55(2):356-366
Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor
Morris C; Chabannon C; Masszi T; Russell N; Nahi H; Kobbe G; Krejci M; Auner HW; Pohlreich D; Hayden P; Basak GW; Lenhoff S; Schaap N; van Biezen A; Knol C; Iacobelli S; Liu Q; Celanovic M; Garderet L; Kroeger N
Article: ACTA HAEMATOLOGICA. 2020;143(5):500-503
Rapid Complete Response to Single-Agent Bcl-2 Inhibitor Venetoclax in a Heart-Transplanted Patient with Triple Refractory Immunoglobulin Light-Chain Amyloidosis
Gran C; Bruchfeld JB; Ellin F; Nahi H
Article: HAEMATOLOGICA. 2019;104(12):2358-2360
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network
Moreau P; Sonneveld P; Boccadoro M; Cook G; Victoria Mateos M; Nahi H; Goldschmidt H; Dimopoulos MA; Lucio P; Blade J; Delforge M; Hajek R; Ludwig H; Facon T; San Miguel JF; Einsele H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(6):588-596
Translocation (11;14) in newly diagnosed multiple myeloma, time to reclassify this standard risk chromosomal aberration?
Gran C; Uttervall K; Bruchfeld JB; Wallblom A; Alici E; Gahrton G; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2019;103(3):247-254
Upfront bortezomib, lenalidomide, and dexamethasone compared to bortezomib, cyclophosphamide, and dexamethasone in multiple myeloma
Uttervall K; Bruchfeld JB; Gran C; Walinder G; Mansson R; Lund J; Gahrton G; Alici E; Nahi H
Article: BLOOD. 2019;134(8):668-677
Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma
Usmani SZ; Nahi H; Mateos M-V; van de Donk NWCJ; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Luo M; Liu K; San-Miguel J
Article: LANCET ONCOLOGY. 2019;20(6):781-794
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; Miguel JS; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2019;380(22):2104-2115
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Attal M; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Chiu C; Wang J; Van Rampelbergh R; Uhlar CM; Kobos R; Qi M; Usmani SZ
Article: LEUKEMIA & LYMPHOMA. 2019;60(2):471-476
Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases
Jurczyszyn A; Davila J; Kortuem KM; Jayabalan DS; Vij R; Fiala M; Milunovic V; Chim CS; Wisniewska-Piaty K; Waszczuk-Gajda A; Crusoe E; Hajek R; Robak P; Razny M; Zawirska D; Bittrich M; Nahi H; Liu J; Castillo JJ; Vesole DH
Article: CANCERS. 2019;11(1):E69-69
Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells
Chrobok M; Dahlberg CIM; Sayitoglu EC; Beljanski V; Nahi H; Gilljam M; Stellan B; Sutlu T; Duru AD; Alici E
Article: LEUKEMIA & LYMPHOMA. 2019;60(1):163-171
Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma
Kumar S; Durie B; Nahi H; Vij R; Dimopoulos MA; Kastritis E; Terpos E; Leleu X; Beksac M; Goldschmidt H; Hillengass J; Su Z; Hutton B; Cameron C; Khan I; Lam A
Article: EUROPEAN JOURNAL OF CANCER. 2019;106:89-98
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
Dimopoulos MA; Grosicki S; Jedrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(1):34-40
A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor
Nahi H; Celanovic M; Liu Q; Lund J; Peceliunas V
Article: PLOS ONE. 2019;14(2):e0211927
Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
Nahi H; Chrobok M; Gran C; Lund J; Gruber A; Gahrton G; Ljungman P; Wagner AK; Alici E
Article: NATURE COMMUNICATIONS. 2018;9(1):3707
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
Went M; Sud A; Forsti A; Halvarsson B-M; Weinhold N; Kimber S; van Duin M; Thorleifsson G; Holroydl A; Johnson DC; Li N; Orlando G; Law PJ; Ali M; Chen B; Mitchell JS; Gudbjartsson DF; Kuiper R; Stephens OW; Bertsch U; Broderick P; Campo C; Bandapalli OR; Einsele H; Gregory WA; Gullberg U; Hillengass J; Hoffmann P; Jackson GH; Joeckel K-H; Johnsson E; Kristinsson SY; Mellqvist U-H; Nahi H; Easton D; Pharoah P; Dunning A; Peto J; Canzian F; Swerdlow A; Eeles RA; Kote-Jarai Z; Muir K; Pashayan N; Nickel J; Noethen MM; Rafnar T; Ross FM; Filho MIDS; Thomsen H; Turesson I; Vangsted A; Andersen NF; Waage A; Walker BA; Wihlborg A-K; Broyl A; Davies FE; Thorsteinsdottir U; Langer C; Hansson M; Goldschmidt H; Kaiser M; Sonneveld P; Stefansson K; Morgans GJ; Hemminki K; Nilsson B; Houlston RS
Article: CANCER MEDICINE. 2018;7(6):2256-2268
Lenalidomide versus lenalidomide plus dexamethasone prolonged treatment after second-line lenalidomide plus dexamethasone induction in multiple myeloma
Lund J; Gruber A; Lauri B; Duru AD; Blimark C; Swedin A; Hansson M; Forsberg K; Ahlberg L; Carlsson C; Waage A; Gimsing P; Vangsted AJ; Frolund U; Holmberg E; Gahrton G; Alici E; Hardling M; Mellqvist U-H; Nahi H
Article: BLOOD. 2018;131(19):2138-2150
Active enhancer and chromatin accessibility landscapes chart the regulatory network of primary multiple myeloma
Jin Y; Chen K; De Paepe A; Hellqvist E; Krstic AD; Metang L; Gustafsson C; Davis RE; Levy YM; Surapaneni R; Wallblom A; Nahi H; Mansson R; Lin YC
Article: HAEMATOLOGICA. 2018;103(5):890-897
Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT
Gagelmann N; Eikema D-J; Iacobelli S; Koster L; Nahi H; Stoppa A-M; Masszi T; Caillot D; Lenhoff S; Udvardy M; Crawley C; Arcese W; Mariette C; Hunter A; Leleu X; Schipperus M; Delforge M; Pioltelli P; Snowden JA; Itala-Remes M; Musso M; van Biezen A; Garderet L; Kroger N
Article: NATURE COMMUNICATIONS. 2018;9(1):1649
The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression
Ali M; Ajore R; Wihlborg A-K; Niroula A; Swaminathan B; Johnsson E; Stephens OW; Morgan G; Meissner T; Turesson I; Goldschmidt H; Mellqvist U-H; Gullberg U; Hansson M; Hemminki K; Nahi H; Waage A; Weinhold N; Nilsson B
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;100(4):386-388
Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients
Gran C; Gahrton G; Alici E; Nahi H
Article: HAEMATOLOGICA. 2018;103(3):506-513
Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry
Blimark CH; Turesson I; Genell A; Ahlberg L; Bjorkstrand B; Carlson K; Forsberg K; Juliusson G; Linder O; Mellqvist U-H; Nahi H; Kristinsson SY
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2018;81(1):183-193
Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial
Falk IJ; Lund J; Green H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist U-H; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Lotfi K; Nahi H
Article: ONCOTARGET. 2017;8(61):103731-103743
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
Alzrigat M; Parraga AA; Majumder MM; Ma A; Jin J; Osterborg A; Nahi H; Nilsson K; Heckman CA; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: LEUKEMIA. 2017;31(11):2435-2442
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
Bahlis NJ; Corso A; Mugge L-O; Shen Z-X; Desjardins P; Stoppa A-M; Decaux O; de Revel T; Granell M; Marit G; Nahi H; Demuynck H; Huang S-Y; Basu S; Guthrie TH; Ervin-Haynes A; Marek J; Chen G; Facon T
Article: LEUKEMIA. 2017;31(11):2443-2448
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study
Kumar SK; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee J-J; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2017;99(3):216-222
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register
Nahi H; Genell A; Walinder G; Uttervall K; Juliusson G; Karin F; Hansson M; Svensson R; Linder O; Carlson K; Bjorkstrand B; Kristinsson SY; Mellqvist UH; Blimark C; Turesson I
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2017;92(8):746-751
IgM myeloma: A multicenter retrospective study of 134 patients
Castillo JJ; Jurczyszyn A; Brozova L; Crusoe E; Czepiel J; Davila J; Dispenzieri A; Eveillard M; Fiala MA; Ghobrial IM; Gozzetti A; Gustine JN; Hajek R; Hungria V; Jarkovsky J; Jayabalan D; Laubach JP; Lewicka B; Maisnar V; Manasanch EE; Moreau P; Morgan EA; Nahi H; Niesvizky R; Paba-Prada C; Pika T; Pour L; Reagan JL; Richardson PG; Shah J; Spicka I; Vij R; Waszczuk-Gajda A; Gertz MA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2017;178(1):61-71
Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study
Sezer O; Beksac M; Hajek R; Sucak G; Cagirgan S; Linkesch W; Akay OM; Gulbas Z; Nahi H; Plesner T; Snowden JA; Timuragaoglu A; Dechow T; Lang A; Tuglular T; Drach J; Armbrecht G; Potamianou A; Couturier C; Olie RA; Feys C; Allietta N; Terpos E
Article: BLOOD ADVANCES. 2017;1(10):619-623
Direct evidence for a polygenic etiology in familial multiple myeloma
Halvarsson B-M; Wihlborg A-K; Ali M; Lemonakis K; Johnsson E; Niroula A; Cibulskis C; Weinhold N; Foersti A; Alici E; Langer C; Pfreundschuh M; Goldschmidt H; Mellqvist U-H; Turesson I; Waage A; Hemminki K; Golub T; Nahi H; Gullberg U; Hansson M; Nilsson B
Article: ONCOTARGET. 2017;8(6):10213-10224
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
Alzrigat M; Parraga AA; Agarwal P; Zureigat H; Osterborg A; Nahi H; Ma A; Jin J; Nilsson K; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2016;175(5):884-891
Characteristics and outcomes of patients with multiple myeloma aged 21-40years versus 41-60years: a multi-institutional case-control study
Jurczyszyn A; Nahi H; Avivi I; Gozzetti A; Niesvizky R; Yadlapati S; Jayabalan DS; Robak P; Pika T; Andersen KT; Rasche L; Madry K; Woszczyk D; Razny M; Usnarska-Zubkiewicz L; Knopinska-Posluszny W; Wojciechowska M; Guzicka-Kazimierczak R; Joks M; Grosicki S; Ciepluch H; Rymko M; Vesole DH; Castillo JJ
Article: BONE MARROW TRANSPLANTATION. 2016;51(12):1569-1572
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009
Rosengren S; Mellqvist U-H; Nahi H; Forsberg K; Lenhoff S; Stromberg O; Ahlberg L; Linder O; Carlson K
Article: BLOOD. 2016;128(20):2415-2422
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Kumar SK; LaPlant BR; Reeder CB; Roy V; Halvorson AE; Buadi F; Gertz MA; Bergsagel PL; Dispenzieri A; Thompson MA; Crawley J; Kapoor P; Mikhael J; Stewart K; Hayman SR; Hwa YL; Gonsalves W; Witzig TE; Ailawadhi S; Dingli D; Go RS; Lin Y; Rivera CE; Rajkumar SV; Lacy MQ
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2016;375(14):1319-1331
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
Dimopoulos MA; Oriol A; Nahi H; San-Miguel J; Bahlis NJ; Usmani SZ; Rabin N; Orlowski RZ; Komarnicki M; Suzuki K; Plesner T; Yoon S-S; Ben Yehuda D; Richardson PG; Goldschmidt H; Reece D; Lisby S; Khokhar NZ; O'Rourke L; Chiu C; Qin X; Guckert M; Ahmadi T; Moreau P
Article: BLOOD. 2016;128(9):1174-1180
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Avet-Loiseau H; Fonseca R; Siegel D; Dimopoulos MA; Spicka I; Masszi T; Hajek R; Rosinol L; Goranova-Marinova V; Mihaylov G; Maisnar V; Mateos M-V; Wang M; Niesvizky R; Oriol A; Jakubowiak A; Minarik J; Palumbo A; Bensinger W; Kukreti V; Ben-Yehuda D; Stewart AK; Obreja M; Moreau P
Article: BLOOD. 2016;128(1):37-44
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
Usmani SZ; Weiss BM; Plesner T; Bahlis NJ; Belch A; Lonial S; Lokhorst HM; Voorhees PM; Richardson PG; Chari A; Sasser AK; Axel A; Feng H; Uhlar CM; Wang J; Khan I; Ahmadi T; Nahi H
Article: EUROPEAN JOURNAL OF HEALTH ECONOMICS. 2016;17(6):711-721
Health resource utilization associated with skeletal-related events: results from a retrospective European study
Body J-J; Pereira J; Sleeboom H; Maniadakis N; Terpos E; Acklin YP; Finek J; Gunther O; Hechmati G; Mossman T; Costa L; Rogowski W; Nahi H; von Moos R
Article: NATURE COMMUNICATIONS. 2016;7:12050
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
Mitchell JS; Li N; Weinhold N; Foersti A; Ali M; van Duin M; Thorleifsson G; Johnson DC; Chen B; Halvarsson B-M; Gudbjartsson DF; Kuiper R; Stephens OW; Bertsch U; Broderick P; Campo C; Einsele H; Gregory WA; Gullberg U; Henrion M; Hillengass J; Hoffmann P; Jackson GH; Johnsson E; Joud M; Kristinsson SY; Lenhoff S; Lenive O; Mellqvist U-H; Migliorini G; Nahi H; Nelander S; Nickel J; Noethen MM; Rafnar T; Ross FM; da Silva Filho MI; Swaminathan B; Thomsen H; Turesson I; Vangsted A; Vogel U; Waage A; Walker BA; Wihlborg A-K; Broyl A; Davies FE; Thorsteinsdottir U; Langer C; Hansson M; Kaiser M; Sonneveld P; Stefansson K; Morgan GJ; Goldschmidt H; Hemminki K; Nilsson B; Houlston RS
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2016;91(6):575-580
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice
Jurczyszyn A; Grzasko N; Gozzetti A; Czepiel J; Cerase A; Hungria V; Crusoe E; Miranda Silva Dias AL; Vij R; Fiala MA; Caers J; Rasche L; Nooka AK; Lonial S; Vesole DH; Philip S; Gangatharan S; Druzd-Sitek A; Walewski J; Corso A; Cocito F; Vekemans M-CM; Atilla E; Beksac M; Leleu X; Davila J; Badros A; Aneja E; Abildgaard N; Kastritis E; Fantl D; Schutz N; Pika T; Butrym A; Olszewska-Szopa M; Usnarska-Zubkiewicz L; Usmani SZ; Nahi H; Chim CS; Shustik C; Madry K; Lentzsch S; Swiderska A; Helbig G; Guzicka-Kazimierczak R; Lendvai N; Waage A; Andersen KT; Murakami H; Zweegman S; Castillo JJ
Article: ACTA ONCOLOGICA. 2016;55(5):554-560
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden
Borg S; Nahi H; Hansson M; Lee D; Elvidge J; Persson U
Article: DRUGS. 2016;76(8):853-867
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma
Moreau P; van de Donk NWCJ; Miguel JS; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos M-V
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2016;374(17):1621-1634
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa A-M; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui A-M; van de Velde H; Richardson PG
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2016;96(1):46-54
Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21
Nahi H; Vatsveen TK; Lund J; Heeg BMS; Preiss B; Alici E; Moller MB; Wader KF; Moller HEH; Groseth LA; Ostergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(12):2039-2051
American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma
Giralt S; Garderet L; Durie B; Cook G; Gahrton G; Bruno B; Hari P; Lokhorst H; McCarthy P; Krishnan A; Sonneveld P; Goldschmidt H; Jagannath S; Barlogie B; Mateos M; Gimsing P; Sezer O; Mikhael J; Lu J; Dimopoulos M; Mazumder A; Palumbo A; Abonour R; Anderson K; Attal M; Blade J; Bird J; Cavo M; Comenzo R; de la Rubia J; Einsele H; Garcia-Sanz R; Hillengass J; Holstein S; Johnsen HE; Joshua D; Koehne G; Kumar S; Kyle R; Leleu X; Lonial S; Ludwig H; Nahi H; Nooka A; Orlowski R; Rajkumar V; Reiman A; Richardson P; Riva E; Miguel JS; Turreson I; Usmani S; Vesole D; Bensinger W; Qazilbash M; Efebera Y; Mohty M; Gasparreto C; Gajewski J; LeMaistre CF; Bredeson C; Moreau P; Pasquini M; Kroeger N; Stadtmauer E
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2015;373(13):1207-1219
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NWCJ; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
Article: CLINICAL CANCER RESEARCH. 2015;21(12):2730-2736
A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma
Hansson M; Gimsing P; Badros A; Niskanen TM; Nahi H; Offner F; Salomo M; Sonesson E; Mau-Sorensen M; Stenberg Y; Sundberg A; Teige I; Van Droogenbroeck J; Wichert S; Zangari M; Frendeus B; Korsgren M; Poelman M; Tricot G
Article: BONE MARROW TRANSPLANTATION. 2015;50(6):808-812
Autologous stem cell transplantation versus novel drugs or conventional chemotherapy for patients with relapsed multiple myeloma after previous ASCT
Grovdal M; Nahi H; Gahrton G; Liwing J; Waage A; Abildgaard N; Pedersen PT; Hammerstrom J; Laaksonen A; Bazia P; Terava V; Ollikainen H; Silvennoinen R; Putkonen M; Anttila P; Porkka K; Remes K
Article: NATURE COMMUNICATIONS. 2015;6:7213
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
Swaminathan B; Thorleifsson G; Joud M; Ali M; Johnsson E; Ajore R; Sulem P; Halvarsson B-M; Eyjolfsson G; Haraldsdottir V; Hultman C; Ingelsson E; Kristinsson SY; Kahler AK; Lenhoff S; Masson G; Mellqvist U-H; Mansson R; Nelander S; Olafsson I; Siguroardottir O; Steingrimsdottir H; Vangsted A; Vogel U; Waage A; Nahi H; Gudbjartsson DF; Rafnar T; Turesson I; Gullberg U; Stefansson K; Hansson M; Thorsteinsdottir U; Nilsson B
Article: EUROPEAN JOURNAL OF MEDICAL GENETICS. 2015;58(4):211-215
A genealogical and clinical study of the phenotypical variation within the Swedish transthyretin His88Arg (p. His108Arg) amyloidosis family
Hellman U; Lundgren H-E; Westermark P; Stafberg C; Nahi H; Tachlinski S; Guggi M; Flogegard M; Hamid M; Escher SA; Suhr OB
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2015;94(4):355-362
TP53 mutations and MDM2^SNP309 identify subgroups of AML patients with impaired outcome
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Green H; Lotfi K; Soderkvist P
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2015;372(2):142-152
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Spicka I; Oriol A; Hajek R; Rosinol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos M-V; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A
Article: PLOS ONE. 2015;10(9):e0138248
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma
Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;167(5):671-680
Impact of ABCB1 single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in FLT3 wild-type de novo AML patients with normal karyotype
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Hoglund M; Palmqvist L; Stockelberg D; Wei Y; Green H; Lotfi K
Article: LANCET ONCOLOGY. 2014;15(11):1195-1206
Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-Miguel JF; Hungria VTM; Yoon S-S; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Guenther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee J-J; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Blade J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang M-C; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa B-R; Binlich F; Richardson PG
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2014;371(10):906-917
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker L; Dimopoulos MA; Dispenzieri A; Catalano J; Belch AR; Cavo M; Pinto A; Weisel K; Ludwig H; Bahlis N; Banos A; Tiab M; Delforge M; Cavenagh J; Geraldes C; Lee J-J; Chen C; Oriol A; de la Rubia J; Qiu L; White DJ; Binder D; Anderson K; Fermand J-P; Moreau P; Attal M; Knight R; Chen G; Van Oostendorp J; Jacques C; Ervin-Haynes A; Avet-Loiseau H; Hulin C; Facon T
Article: ONCOLOGIST. 2014;19(8):829-844
European Perspective on Multiple Myeloma Treatment Strategies in 2014
Ludwig H; Sonneveld P; Davies F; Blade J; Boccadoro M; Cavo M; Morgan G; de la Rubia J; Delforge M; Dimopoulos M; Einsele H; Facon T; Goldschmidt H; Moreau P; Nahi H; Plesner T; San-Miguel J; Hajek R; Sondergeld P; Palumbo A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2014;164(5):684-693
Improved survival in myeloma patients: starting to close in on the gap between elderly patients and a matched normal population
Liwing J; Uttervall K; Lund J; Aldrin A; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Kviele HH; Johansson P; Lauri B; Mellqvist U-H; Swedin A; Svensson M; Nasman P; Alici E; Gahrton G; Aschan J; Nahi H
Article: PLOS ONE. 2014;9(7):e101819
The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal Impairment
Uttervall K; Duru AD; Lund J; Liwing J; Gahrton G; Holmberg E; Aschan J; Alici E; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;92(1):19-25
Addition of thalidomide to melphalan and prednisone treatment prolongs survival in multiple myeloma - a retrospective population based study of 1162 patients
Lund J; Uttervall K; Liwing J; Gahrton G; Alici E; Aschan J; Holmberg E; Nahi H
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2013;88(12):1001-1006
Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′-nucleotidase
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Hoglund M; Palmqvist L; Stockelberg D; Wei Y; Green H; Lotfi K
Article: BLOOD. 2013;121(23):4647-4654
Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
Mellqvist U-H; Gimsing P; Hjertner O; Lenhoff S; Laane E; Remes K; Steingrimsdottir H; Abildgaard N; Ahlberg L; Blimark C; Dahl IM; Forsberg K; Gedde-Dahl T; Gregersen H; Gruber A; Guldbrandsen N; Haukas E; Carlson K; Kvam AK; Nahi H; Lindas R; Andersen NF; Turesson I; Waage A; Westin J
Article: ACTA HAEMATOLOGICA. 2013;130(1):7-15
A Combination Regimen of Bortezomib, Cyclophosphamide and Betamethasone Gives Quicker, Better and More Durable Response than VAD/CyBet Regimens: Results from a Swedish Retrospective Analysis
Uttervall K; Admasie J; Alici E; Lund J; Liwing J; Aschan J; Barendse M; Deneberg S; Mellqvist U-H; Carlson K; Nahi H
Article: DRUGS OF THE FUTURE. 2013;38(8):545-554
DARATUMUMAB Anti-CD38 Monoclonal Antibody, Treatment of Multiple Myeloma
Richardson P; Lokhorst H; Palumbo A; Nahi H; Laubach J; Gimsing P; Lisby S; Cakana A; Brun NC; Plesner T
Article: MEDICAL ONCOLOGY. 2012;29(4):2348-2358
Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution
Nahi H; Remberger M; Machaczka M; Ungerstedt J; Mattson J; Ringden O; Le-Blanc K; Ljungman P; Hagglund H
Article: MEDICAL ONCOLOGY. 2012;29(3):2191-2199
Autologous hematopoietic stem cell transplantation in multiple myeloma and lymphoma: an analysis of factors influencing stem cell collection and hematological recovery
Ungerstedt JS; Watz E; Uttervall K; Johansson B-M; Wahlin BE; Nasman P; Ljungman P; Gruber A; Nygell UA; Nahi H
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2012;88(6):485-496
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study
Hjorth M; Hjertner O; Knudsen LM; Gulbrandsen N; Holmberg E; Pedersen PT; Andersen NF; Andreasson B; Billstrom R; Carlson K; Carlsson MS; Flogegard M; Forsberg K; Gimsing P; Karlsson T; Linder O; Nahi H; Othzen A; Swedin A
Article: PHARMACOGENOMICS JOURNAL. 2012;12(2):111-118
Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype
Green H; Falk IJ; Lotfi K; Paul E; Hermansson M; Rosenquist R; Paul C; Nahi H
Article: LEUKEMIA. 2012;26(1):149-157
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Kumar SK; Lee JH; Lahuerta JJ; Morgan G; Richardson PG; Crowley J; Haessler J; Feather J; Hoering A; Moreau P; LeLeu X; Hulin C; Klein SK; Sonneveld P; Siegel D; Blade J; Goldschmidt H; Jagannath S; Miguel JS; Orlowski R; Palumbo A; Sezer O; Rajkumar SV; Durie BGM
Article: BLOOD. 2011;118(20):5573-5582
Prognostic DNA methylation patterns in cytogenetically normal acute myeloid leukemia are predefined by stem cell chromatin marks
Deneberg S; Guardiola P; Lennartsson A; Qu Y; Gaidzik V; Blanchet O; Karimi M; Bengtzen S; Nahi H; Uggla B; Tidefelt U; Hoglund M; Paul C; Ekwall K; Doehner K; Lehmann S
Article: MEDICAL ONCOLOGY. 2011;28(2):539-543
Acquired hemophagocytic lymphohistiocytosis associated with multiple myeloma
Machaczka M; Vaktnas J; Klimkowska M; Nahi H; Hagglund H
Article: ONCOLOGIST. 2011;16(4):388-403
Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective
Ludwig H; Beksac M; Blade J; Cavenagh J; Cavo M; Delforge M; Dimopoulos M; Drach J; Einsele H; Facon T; Goldschmidt H; Harousseau J-L; Hess U; Kropff M; da Costa FL; Louw V; Magen-Nativ H; Mendeleeva L; Nahi H; Plesner T; San-Miguel J; Sonneveld P; Udvardy M; Sondergeld P; Palumbo A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;86(3):206-215
APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells
Ali D; Jonsson-Videsater K; Deneberg S; Bengtzen S; Nahi H; Paul C; Lehmann S
Article: CYTOTHERAPY. 2010;12(8):1044-1055
Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor
Sutlu T; Stellan B; Gilljam M; Quezada HC; Nahi H; Gahrton G; Alici E
Article: LEUKEMIA RESEARCH. 2010;34(12):1627-1629
Constitutional inv(3) in myelodysplastic syndromes
Gahrton C; Nahi H; Jansson M; Wallblom A; Alici E; Sutlu T; Samuelsson J; Gahrton G
Article: LEUKEMIA. 2010;24(5):932-941
Gene-specific and global methylation patterns predict outcome in patients with acute myeloid leukemia
Deneberg S; Grovdal M; Karimi M; Jansson M; Nahi H; Corbacioglu A; Gaidzik V; Doehner K; Paul C; Ekstrom TJ; Hellstrom-Lindberg E; Lehmann S
Article: LEUKEMIA & LYMPHOMA. 2009;50(9):1512-1518
Low p14ARF expression in de novo acute myeloid leukemia with normal karyotype is associated with poor survival
Paul E; Uggla B; Deneberg S; Bengtzen S; Hermansson M; Dahlman I; Rosenquist R; Wiman KG; Nahi H
Article: ONCOLOGY REPORTS. 2009;22(1):137-142
Impact of chromosome 13 deletion and plasma cell load on long-term survival of patients with multiple myeloma undergoing autologous transplantation
Paul E; Sutlu T; Deneberg S; Alici E; Bjorkstrand B; Jansson M; Lerner R; Wallblom A; Gahrton G; Nahi H
Article: HAEMATOLOGICA. 2008;93(11):1734-1738
An investigation into whether deletions in 9p reflect prognosis in adult precursor B-cell acute lymphoblastic leukemia: a multi-center study of 381 patients
Nahi H; Hagglund H; Ahlgren T; Bernell P; Hardling M; Karlsson K; Lazarevic VL; Linderholm M; Smedmyr B; Astrom M; Hallbook H
Article: CANCER CHEMOTHERAPY AND PHARMACOLOGY. 2008;62(3):439-448
The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia
Mollgard L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsater K; Fioretos T; Andersson A; Paul C; Lehmann S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453
Mutated and non-mutated TP53 as targets in the treatment of leukaemia
Nahi H; Selivanova G; Lehmann S; Mollgard L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Article: BLOOD. 2008;111(6):3155-3162
Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components
Alici E; Sutlu T; Boejrkstrand B; Gilljam M; Stellan B; Nahi H; Quezada HC; Gahrton G; Ljunggren H-G; Dilber MS
Article: LEUKEMIA & LYMPHOMA. 2008;49(3):508-516
Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia
Nahi H; Lehmann S
Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2007;31(1):153-160
Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia
Uggla B; Tina E; Nahi H; Paul C; Hoglund M; Sirsjo A; Tidefelt U
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(3):367-373
Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens
Merup M; Lazarevic V; Nahi H; Andreasson B; Malm C; Nilsson L; Brune M; LeBlanc K; Kutti J; Birgegard G
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236
PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion
Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2005;130(1):96-98
Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study
Ljungman P; Nahi H; Linde A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291
Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
Show more

All other publications

Letter: BLOOD CANCER JOURNAL. 2024;14(1):65
In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease
Lund T; Gundesen MT; Vangsted AJ; Helleberg C; Haukas E; Silkjaer T; Asmussen JT; Teodorescu EM; Jensen BA; Slordahl TS; Nahi H; Waage A; Abildgaard N; Schjesvold F
Meeting abstract: BLOOD. 2023;142:1960
A Novel Biosignature for Potential Stratification and Elucidation of Newly Diagnosed Multiple Myeloma Patients at-Risk
Kashif M; Zhou Y; Luong V; Uttervall K; Gahrton G; Nahi H; Alici E; Lund J
Letter: BLOOD CANCER JOURNAL. 2023;13(1):105
Potential value of pre-planned imaging of bone disease in multiple myeloma
Gundesen M; Asmussen JT; Schjesvold F; Vangsted AJ; Helleberg C; Haukas E; Silkjaer T; Teodorescu EM; Jensen BAS; Slordahl T; Nahi H; Waage A; Abildgaard N; Lund T
Editorial comment: FUTURE ONCOLOGY. 2023;19(13):887-895
Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; Perrot A; Weisel K; Raje N; Macro M; Frenzel L; Leleu X; Wang J; Van Rampelbergh R; Uhlar CM; Vermeulen J; Duran J; Borgsten F; Usmani SZ
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;110(2):224-225
Response to Caravita di Toritto and Rago
Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H; Afram G
Letter: LEUKEMIA & LYMPHOMA. 2023;64(2):468-472
Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab: part 3 of the open-label, multicenter, phase 1b PAVO study
Nahi H; Usmani SZ; Mateos M-V; van de Donk NWCJ; Oriol A; Plesner T; Bandyopadhyay N; Hellemans P; Tromp B; Nnane I; Zemlickis D; Chari A; Moreau P
Meeting abstract: BLOOD. 2022;140:1142-1145
Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Perrot A; Facon T; Plesner T; Usmani S; Kumar SK; Bahlis NJ; Hulin C; Orlowski RZ; Nahi H; Mollee P; Ramasamy K; Roussel M; Jaccard A; Delforge M; Karlin L; Arnulf B; Chari A; Pei H; Gupta N; Kaila S; Matt K; Gries KS; Carson R; Borgsten F; Weisel K
Meeting abstract: BLOOD. 2022;140:10133-10136
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon T; Kumar SK; Weisel K; Usmani S; Moreau P; Plesner T; Orlowski RZ; Bahlis NJ; Basu S; Nahi H; Hulin C; Quach H; O'Dwyer M; Perrot A; Venner CP; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Pei H; Carson R; Borgsten F; Goldschmidt H
Meeting abstract: BLOOD. 2022;140:7297-7300
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Moreau P; Facon T; Usmani S; Bahlis NJ; Raje N; Plesner T; Orlowski RZ; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Tiab M; Macro M; Frenzel L; Leleu X; Pei H; Krevvata M; Carson R; Borgsten F; Kumar SK
Meeting abstract: BLOOD. 2022;140:10150-10153
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study
Kumar SK; Moreau P; Bahlis NJ; Facon T; Plesner T; Orlowski RZ; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Pei H; Krevvata M; Carson R; Borgsten F; Usmani S
Meeting abstract: BLOOD. 2022;140:12605-12606
Teclistamab for Relapsed/Refractory Multiple Myeloma: Real-World Experience in an Early Access Program
Uttervall K; Nahi H; Kashif M; Lemonakis K; Rosengren S; Brolin J; Lund J; Hansson M
Meeting abstract: BLOOD. 2021;138:4095
Meaningful Changes in Patient-Reported Outcomes in Relation to Best Clinical Response and Disease Progression: Post Hoc Analyses from MAIA
Perrot A; Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis NJ; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer ME; Venner CP; Weisel K; Mace JR; Raje NS; Tiab M; Macro M; Frenzel L; Leleu X; Liu K; Fastenau J; Gries KS; Ho KF; Mistry P; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Meeting abstract: BLOOD. 2021;138:1667
Subcutaneous Daratumumab with Rapid Corticosteroid Tapering in Relapsed or Refractory Multiple Myeloma Patients: Part 3 Update of the Open-Label, Multicenter, Phase 1b Pavo Study
Nahi H; Usmani SZ; Mateos M-V; van de Donk NWCJ; Moreau P; Oriol A; Plesner T; Bandyopadhyay N; Hellemans P; Tromp B; Nnane I; Zemlickis D; Farnsworth A; Chari A
Meeting abstract: BLOOD. 2021;138:896
Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Moreau P; Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel J; Oriol A; Nooka AK; Martin T; Rosino L; Chari A; Karlin L; Benboubker L; Mateos M-V; Bahlis NJ; Popat R; Besemer B; Martínez-López J; Sidana S; Pei L; Trancucci D; Verona RI; Girgis S; Olyslager Y; Jaffe M; Uhlar CM; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan AY
Meeting abstract: BLOOD. 2021;138:1646
Efficacy of Daratumumab, Lenalidomide, and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma and Impaired Renal Function from the Phase 3 Maia Study Based on Lenalidomide Starting Dose
Usmani SZ; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis NJ; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer ME; Perrot A; Venner CP; Weisel K; Mace JR; Raje NS; Tiab M; Macro M; Frenzel L; Leleu X; Pei H; Van Rampelbergh R; Tromp B; Delioukina M; Facon T
Meeting abstract: BLOOD. 2021;138:1655
Sustained Improvement in HealthRelated Quality of Life in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial
Perrot A; Facon T; Kumar S; Plesner T; Orlowski RZ; Moreau P; Bahlis NJ; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer ME; Venner CP; Weisel K; Mace JR; Raje NS; Tiab M; Macro M; Frenzel L; Leleu X; Liu K; Fastenau J; Gries KS; Ho KF; Mistry P; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Meeting abstract: BLOOD. 2021;138:4796
CD38 Down-Regulation on Ex Vivo Activated and Expanded NK Cells for Cell Therapy Persists after Infusion
Nahi H; Chrobook M; Meinke S; Gran C; Marquardt N; Afram G; Sutlu T; Gilljam M; Stellan B; Wagner AK; Walther-Jallow L; Liwing J; Klimkowska M; Gahrton G; Ljungman P; Ljunggren H-G; Alici E
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(11):E443-E446
Antibody response to COVID-19 mRNA vaccine (Comirnaty) in myeloma patients treated with high-dose melphalan and/or immunotherapy
Lockmer S; Uttervall K; Kashif M; Svard C; Malmsten K; Fletcher-Torres E; Alici E; Lund J; Nahi H
Editorial comment: CLINICAL CHEMISTRY. 2021;67(10):1309-1311
Predicting Drug Resistance by Single-Cell RNASeq in Patients with Multiple Myeloma
Kashif M; Alici E; Nahi H
Letter: INTERNATIONAL JOURNAL OF DERMATOLOGY. 2021;60(7):e271-e273
Pyoderma gangrenosum with plasma cell dyscrasia should be subject for anti-myeloma treatment
Nahi H; Afram G; Brauner H; Talme T; Kuzmina N
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(15):8007
Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
Krishnan AY; Garfall AL; Mateos M-V; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Goldberg JD; Banerjee A; Usmani SZ
Letter: BLOOD. 2021;137(9):1260-1263
Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder
Klimkowska M; Nannya Y; Gran C; Mansson R; Douagi I; Ogawa S; Nahi H; Tobiasson M
Review: LANCET ONCOLOGY. 2021;22(3):e105-e118
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
Moreau P; Kumar SK; Miguel JS; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; Donk NVD; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; Joao C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; Vangsted A; Weisel K; Baz R; Hungria V; Berdeja JG; da Costa FL; Maiolino A; Waage A; Vesole DH; Ocio EM; Quach H; Driessen C; Blade J; Leleu X; Riva E; Bergsagel PL; Hou J; Chng WJ; Mellqvist U-H; Dytfeld D; Harousseau J-L; Goldschmidt H; Laubach J; Munshi NC; Gay F; Beksac M; Costa LJ; Kaiser M; Hari P; Boccadoro M; Usmani SZ; Zweegman S; Holstein S; Sezer O; Harrison S; Nahi H; Cook G; Mateos M-V; Rajkumar SV; Dimopoulos MA; Richardson PG
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2021;96(3):E63-E65
Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression
Gran C; Luong V; Bruchfeld JB; Liwing J; Afram G; Lund J; Usmani S; Alici E; Nahi H
Meeting abstract: BLOOD. 2020;136:1-2
Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Richardson PG; Nooka A; Quach H; Trudel S; Routledge D; Song K; Nahi H; Paul S; Khan J; Brouch M; Ferron-Brady G; Yeakey A; Shelton C; de Oca RM; Smith LM; Im E; Ahlers CM; Paul EM; Holkova B; Gupta I; Kremer BE; Rodriguez-Otero P
Meeting abstract: BLOOD. 2020;136:27
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Garfall AL; Usmani SZ; Mateos M-V; Nahi H; van de Donk NWCJ; San-Miguel JF; Rocafiguera AO; Rosinol L; Chari A; Bhutani M; Pei L; Verona R; Girgis S; Stephenson T; Goldberg JD; Banerjee A; Krishnan A
Meeting abstract: BLOOD. 2020;136:20
Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients
Silvennoinen RH; Nahi H; Anttila P; Koskenvesa P; Lievonen J; Marttila A; Varmavuo V; Sikio A; Nurmi M; Saily M; Partanen A; Sankelo M; Luoma S; Mantymaa P; Ilveskero S; Eshoj HR; Nielsen LK; Jantunen E; Heckman CA
Meeting abstract: BLOOD. 2020;136:40-41
A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients
Silvennoinen RH; Waage A; Peceliunas V; Schjesvold F; Mdphd; Anttila P; Saily M; Putkonen M; Carlson K; Haukaas E; Sankelo M; Partanen A; Szatkowski DL; Hansson M; Marttila A; Ahlberg L; Axelsson P; Lauri B; Mikkola MH; Karlsson C; Abelsson J; Ahlstrand E; Sikio A; Klimkowska M; Matuzeviciene R; Fenstad MH; Ilveskero S; Nahi H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(5):e213-e217
Treosulfan conditioning for allogeneic transplantation in multiple myeloma - improved overall survival in first line haematopoietic stem cell transplantation - a large retrospective study by the Chronic Malignancies Working Party of the EBMT
Gran C; Wang J; Nahi H; Koster L; Gahrton G; Einsele H; Niittyvoupio R; Edinger M; Beelen D; Ciceri F; Bornhaeuser M; Finke J; de Wreede LC; Ljungman P; Mielke S; Tischer J; Garderet L; Schoenland S; Yakoub-Agha I; Kroeger N
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(15):100
Phase I study of teclistamab, a humanized B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in relapsed/refractory multiple myeloma (R/R MM).
Usmani SZ; Mateos M-V; Nahi H; Krishnan AY; van de Donk NWCJ; San Miguel J; Oriol A; Rosinol L; Chari A; Adams H; Girgis S; Lin SXW; Stephenson T; Kemmerer K; Smit J; Elsayed YA; Infante JR; Goldberg JD; Banerjee A; Garfall AL
Corrigendum: LANCET HAEMATOLOGY. 2020;7(10):E710
newly diagnosed patients ineligible for transplants (vl 7, pg e370, 2020)
Mateos M-V; Nahi H; Legiec W
Meeting abstract: BLOOD. 2019;134:lba-6
Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)
Usmani SZ; Quach H; Mateos M-V; Landgren O; Leleu X; Siegel DS; Weisel K; Yang H; Klippel ZK; Zahlten-Kumeli A; Dimopoulos MA
Meeting abstract: BLOOD. 2019;134:4575
Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017
Hayden PJ; Eikema D-J; Koster L; Goldschmidt H; Blaise D; Potter M; Touzeau C; Huynh A; Byrne J; Hulin C; Rabin NK; Benjamin R; Cornelissen JJ; Nahi H; Cook G; Gribben JG; Meijer E; Remenyi P; Mayer J; Tsirigotis P; Bernardeschi P; Beksac M; Schoenland SO; Yakoub-Agha I
Meeting abstract: BLOOD. 2019;134:1875
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
Bahlis N; Facon T; Usmani SZ; Kumar SK; Plesner T; Orlowski RZ; Touzeau C; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer ME; Venner CP; Weisel KC; Krevvata M; Pei H; Wang J; Van Rampelbergh R; Ukropec J; Uhlar CM; Kobos R; Perrot A
Meeting abstract: BLOOD. 2019;134:3151
Daratumumab (DARA) Subcutaneous (SC) Delivery in Relapsed or Refractory Multiple Myeloma (RRMM): Population Pharmacokinetics (PPK) and Exposure-Response (E-R) Analysis
Luo M; Parasrampuria DA; Usmani SZ; Mateos M-V; Nahi H; Heuck C; Qi M; Sun S; Clemens PL; Zhou H; Sun Y-NT; Xu S
Meeting abstract: BLOOD. 2019;134:1865
Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients with Relapsed or Refractory Multiple Myeloma: Columba Update
Usmani SZ; Mateos M-V; Nahi H; Grosicki S; Vorobyev VI; Spicka I; Hungria VTM; Korenkova S; Flogegard M; Blade J; Moreau P; Kaiser MF; Iida S; Laubach JP; Masterson T; Lantz KA; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Qi M; Bahlis N
Meeting abstract: BLOOD. 2019;134:1906
Randomized, Open-Label, Non-Inferiority, Phase 3 Study of Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) Administration in Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM): Body Weight Subgroup Analysis of Columba
Mateos M-V; Usmani SZ; Grosicki S; Vorobyev VI; Spicka I; Hungria VTM; Korenkova S; Bahlis N; Flogegard M; Blade J; Moreau P; Kaiser MF; Iida S; Laubach JP; Masterson T; Lantz KA; O'Rourke L; Qin X; Parasrampuria DA; Heuck C; Qi M; Nahi H
Meeting abstract: BLOOD. 2019;134:601
A Randomized Phase 2 Trial Comparing Carfilzomib-Dexamethasone Vs Observation As Maintenance after Induction with Carfilzomib-Cyclophosphamide-Dexamethasone in Salvage ASCT in Multiple Myeloma: A Trial By the Nordic Myeloma Study Group
Gregersen H; Peceliunas V; Remes K; Schjesvold FH; Abildgaard N; Nahi H; Andersen NF; Vangsted AJ; Klausen TW; Helleberg C; Carlson K; Frolund UC; Axelsson P; Stromberg O; Blimark CH; Linder O; Tsykunova G; Waage A; Hansson M; Gulbrandsen N
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E279-E280
A phase 2 study of carfilzomib plus elotuzumab plus dexamethasone for myeloma patients relapsed after 1-3 prior treatment lines
Silvennoinen R; Majumder MM; Tsallos D; Nahi H; Anttila P; Partanen A; Luoma S; Sikio A; Nurmi M; Varmavuo V; Saily M; Sankelo M; Jantunen E; Pelliniemi T-T; Ilveskero S; Eshoj HR; Nielsen LK; Eldfors S; Leppae A-M; Heckman C
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E247-E248
Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA
Usmani S; Mateos M-V; Hungria V; Iida S; Bahlis NJ; Nahi H; Magen H; Cavo M; Hulin C; White D; De Stefano V; Slavcev M; Heuck C; Qin X; Masterson T; Lantz K; Gries K
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E225-E226
Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant
Gries K; Facon T; Plesner T; Usmani S; Kumar S; Orlowski RZ; Bahlis NJ; Nahi H; Mollee P; Ramasamy K; Roussel M; Delforge M; Karlin L; Arnulf B; Chari A; Hulin C; Weisel K; He J; Ho KF; Wang J; Van Rampelbergh R; Uhlar C; Kobos R; Perrot A
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E209
Over 10 years relative median survival in MM patients ≤ 65 years with VGPR or better on 1st line treatment. Population-based data on patients diagnosed 2008-2018 from the Swedish Myeloma Registry
Blimark CH; Genell A; Lund J; Nahi H; Carlson K; Forsberg K; Juliusson G; Lauri B; Linder O; Danielsson S; Svensson R; Vesskovski L; Knut-Bojanowska D; Turesson I
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E206
Treosulfan Conditioning for Allogeneic Transplantation in Multiple Myeloma - Improved Overall Survival in first line Hematopoietic Stem Cell Transplantation
Gran C; Wang J; Nahi H; Koster L; Gahrton G; Wolschke C; Einsele H; Niittyvoupio R; Blaise D; Niederwieser D; Meier E; Petersen E; de Wreede LC; Ljungman P; Bourhis JH; Veelken H; Beelen D; Stelljes M; Gerbitz A; Vincent L; Finke J; Passweg J; Milpied N; Stoelzel F; Yakoub-Agha I; Schoenland S; Garderet L; Kroger N
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E158
Reinstating anti-tumor activity of Natural Killer cells
Caliskan C; Chrobok M; Wagner AK; Bruchfeld JB; Nahi H; Alici E
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2019;19(10):E170
Novel RNA construct increases cytotoxic proteins in lymphocytes and leads to prolonged survival in an experimental syngeneic immunocompetent Multiple Myeloma model
Wagner AK; Baloch AH; Chrobok M; Dahlberg C; Gahrton G; Nahi H; Ljunggren H-G; Alici E
Corrigendum: NATURE COMMUNICATIONS. 2019;10(1):213
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (vol 9, 3707, 2018)
Went M; Sud A; Foersti A; Halvarsson B-M; Weinhold N; Kimber S; van Duin M; Thorleifsson G; Holroyd A; Johnson DC; Li N; Orlando G; Law PJ; Ali M; Chen B; Mitchell JS; Gudbjartsson DF; Kuiper R; Stephens OW; Bertsch U; Broderick P; Campo C; Bandapalli OR; Einsele H; Gregory WA; Gullberg U; Hillengass J; Hoffmann P; Jackson GH; Joeckel K-H; Johnsson E; Kristinsson SY; Mellqvist U-H; Nahi H; Easton D; Pharoah P; Dunning A; Peto J; Canzian F; Swerdlow A; Eeles RA; Kote-Jarai Z; Muir K; Pashayan N; Henderson BE; Haiman CA; Benlloch S; Schumacher FR; Al Olama AA; Berndt SI; Conti DV; Wiklund F; Chanock S; Stevens VL; Tangen CM; Batra J; Clements J; Gronberg H; Schleutker J; Albanes D; Weinstein S; Wolk A; West C; Mucci L; Cancel-Tassin G; Koutros S; Sorensen KD; Grindedal EM; Neal DE; Hamdy FC; Donovan JL; Travis RC; Hamilton RJ; Ingles SA; Rosenstein B; Lu Y-J; Giles GG; Kibel AS; Vega A; Kogevinas M; Penney KL; Park JY; Stanford JL; Cybulski C; Nordestgaard BG; Brenner H; Maier C; Kim J; John EM; Teixeira MR; Neuhausen SL; De Ruyck K; Razack A; Newcomb LF; Lessel D; Kaneva R; Usmani N; Claessens F; Townsend PA; Gago-Dominguez M; Roobol MJ; Menegaux F; Khaw K-T; Cannon-Albright L; Pandha H; Thibodeau SN; Nickel J; Noethen MM; Rafnar T; Ross FM; Filho MIDS; Thomsen H; Turesson I; Vangsted A; Andersen NF; Waage A; Walker BA; Wihlborg A-K; Broyl A; Davies FE; Thorsteinsdottir U; Langer C; Hansson M; Goldschmidt H; Kaiser M; Sonneveld P; Stefansson K; Morgan GJ; Hemminki K; Nilsson B; Houlston RS
Meeting abstract: BLOOD. 2018;132:2143
Impact of Upfront Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma with Del(17) and t(4;14): A Report from the EBMT Chronic Malignancies Working Party
Gagelmann N; Eikema D-J; Iacobelli S; Schoemans H; Koster L; Caillot D; Blaise D; Remenyi P; Bulabois C-E; Passweg JR; Leleu X; Zver S; Kobbe G; Rambaldi A; Chevallier P; Ringhoffer M; Martin AM; Salmenniemi U; Poire X; Lenhoff S; Pioltelli P; Mordini N; Nahi H; Schoenland S; Garderet L; Yakoub-Agha I; Kroeger N
Meeting abstract: BLOOD. 2018;132:1995
Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Chari A; Mateos M-V; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Nahi H; Tang J; Hellemans P; Tromp B; Clemens PL; Farnsworth A; San-Miguel JF; Usmani SZ
Meeting abstract: BLOOD. 2018;132:2006
Pharmacokinetics (PK) of Subcutaneous Daratumumab in Patients with Relapsed or Refractory (RR) Multiple Myeloma (MM): Primary Clinical Pharmacology Analysis of the Open-Label, Multicenter, Phase 1b Study (PAVO)
Clemens PL; Xu S; Luo M; Chari A; Usmani SZ; Mateos M-V; van de Donk NWCJ; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; San-Miguel JF; Sun XY-N; Farnsworth A; Masterson T; Hellemans P; Qi M; Nahi H
Meeting abstract: BLOOD. 2018;132:3308
Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials
Szabo AG; Minnema MC; Nahi H; Plesner T
Meeting abstract: BLOOD. 2018;132:lba-2-lba-2
Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Ahmadi T; Chiu C; Wang J; Van Rampelbergh R; Uhlar CM; Kobos R; Qi M; Usmani SZ
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):8013
Subcutaneous daratumumab (DARA) in patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1b study (PAVO).
Chari A; Usmani SZ; Mateos M-V; Van De Donk N; Kaufman JL; Moreau P; Rocafiguera AO; Plesner T; Benboubker L; Liu K; Hellemans P; Masterson TJ; Clemens PL; Farnsworth A; Nahi H; San-Miguel J
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2018;36(15):tps8058
Randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients with relapsed or refractory multiple myeloma (RRMM): COLUMBA.
Usmani SZ; Mateos M-V; Bahlis NJ; Grosicki S; Spencer A; Bandekar R; Masterson TJ; Clemens PL; Heuck CJ; Qi M; Nahi H
Meeting abstract: VALUE IN HEALTH. 2017;20(9):A548
ESTIMATES OF PFS, TTNT PER TREATMENT LINE AND THEIR RELATIONSHIP FOR MULTIPLE MYELOMA PATIENTS
Vago E; Liwing J; Pan R; Mehra M; Zheng Y; Nahi H
Meeting abstract: VALUE IN HEALTH. 2017;20(9):A408
PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Dimopoulos M; Sonneveld P; Nahi H; Kumar S; Hashim M; Kulakova M; Duran M; Heeg B; Lam A; Dearden L
Meeting abstract: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2017;17:S333-S334
An Open-label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib, Cyclophosphamide, and Dexamethasone (ICd) in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM)
Dimopoulos M; Grosicki S; Jedrzejczak W; Nahi H; Gruber A; Hansson M; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
Meeting abstract: CANCER RESEARCH. 2017;77:5030
The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients
Falk IJ; Lund J; Green H; Gruber A; Alici E; Lauri B; Blimark C; Mellqvist U-H; Swedin A; Forsberg K; Carlsson C; Hardling M; Ahlberg L; Nahi H; Lotfi K
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2017;35:8025
Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety update (POLLUX).
Bahlis NJ; Moreau P; Nahi H; Plesner T; Goldschmidt H; Suzuki K; Orlowski RZ; Rabin N; Leiba M; Oriol A; Chari A; Miguel JS; Richardson PG; Usmani SZ; O'Rourke LM; Wu K; Casneuf T; Chiu C; Qin X
Meeting abstract: EUROPEAN PSYCHIATRY. 2017;41:S724
Religious beliefs and post-traumatic growth following stillbirth in a sample Moroccan women
Goutaudier N; Nahi H; Boudoukha AH; Sejourne N; Chabrol H
Meeting abstract: BLOOD. 2016;128(22):5692
Improved Safety with the Use of Subcutaneous Bortezomib in Combination with Panobinostat and Dexamethasone: Preliminary Data from a Panobinostat Global Expanded Treatment Protocol
Guenther A; Mugge L-O; Haenel M; Schjesvold FH; Lechner D; Yaser S; Hebart H; Gisslinger H; Greil R; Gunsilius E; Goerner M; Weisel K; Durig J; Elemary M; Wolleschak D; Klein SA; Munder M; Kiani A; Nahi H; Junghanss C; Campello-Iddison V; Deniau Y; Feng X; Einsele H
Meeting abstract: BLOOD. 2016;128(22):4414
Natural History of Relapsed Myeloma, Refractory to Immunomodulatory Drugs and Proteasome Inhibitors: A Multicenter IMWG Study
Kumar S; Dimopoulos MA; Kastritis E; Terpos E; Nahi H; Goldschmidt H; Hillengass J; Leleu X; Beksac M; Alsina M; Oriol A; Cavo M; Ocio EM; Mateos MV; O'Donnell EK; Vij R; Lokhorst HM; van de Donk NWCJ; Min C-K; Mark T; Turesson I; Hansson M; Ludwig H; Jagannath S; Delforge M; Kyriakou C; Hari P; Mellqvist U-H; Usmani SZ; Dytfeld D; Badros AZ; Moreau P; Kim K; Otero PR; Lee JH; Shustik C; Waller D; Chng WJ; Ozaki S; Lee J-J; de la Rubia J; Eom HS; Rosinol L; Lahuerta JJ; Sureda A; Kim JS; Durie BGM
Meeting abstract: BLOOD. 2016;128(22):3276
IgM Myeloma: A Multicenter Retrospective Study of 159 Patients
Castillo JJ; Jurczyszyn AJ; Crusoe E; Czepiel J; Davila J; Dispenzieri A; Eveillard M; Fiala MA; Ghobrial IM; Gozzetti A; Gustine J; Hajek R; Hungria V; Jarkovsky J; Jayabalan D; Laubach JP; Lewicka B; Maisnar V; Manasanch EE; Moreau P; Nahi H; Niesvizky R; Paba-Prada CE; Pika T; Pour L; Reagan JL; Richardson PG; Shah JJ; Spicka I; Vij R; Waszczuk A; Gertz MA
Meeting abstract: BLOOD. 2016;128(22):246
Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone
Avet-Loiseau H; Casneuf T; Chiu C; Laubach JP; Lee J-J; Moreau P; Plesner T; Nahi H; Khokhar NZ; Qi M; Schecter J; Carlton V; Qin X; Liu K; Wu K; Zhuang SH; Ahmadi T; Sasser AK; San-Miguel J
Meeting abstract: BLOOD. 2016;128(22):2266
Impact of Extramedullary Disease in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation: A Study By the EBMT Chronic Malignancies Working Party
Gagelmann N; Iacobelli S; Koster L; Nahi H; Stoppa A-M; Masszi T; Caillot D; Lenhoff S; Udvardy M; Crawley C; Arcese W; Mariette C; Hunter A; Leleu X; Schipperus M; Delforge M; Pioltelli P; Snowden JA; Itala-Remes M; Musso M; Garderet L; Kroger N
Meeting abstract: BLOOD. 2016;128(22):1149
Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma (PAVO)
Usmani SZ; Nahi H; Mateos M-V; Lokhorst HM; Chari A; Kaufman JL; Moreau P; Oriol A; Plesner T; Benboubker L; Hellemans P; Masterson T; Clemens PL; Ahmadi T; Liu K; San-Miguel J
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2016;174(3):473-477
Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach
Alici E; Chrobok M; Lund J; Ahmadi T; Khan I; Duru AD; Nahi H
Corrigendum: DRUGS. 2016;76(9):989-990
Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (vol 76, pg 853, 2016)
Moreau P; van de Donk NWCJ; San Miguel J; Lokhorst H; Nahi H; Ben-Yehuda D; Cavo M; Cook G; Delforge M; Einsele H; Zweegman S; Ludwig H; Driessen C; Palumbo A; Facon T; Plesner T; Dimopoulos M; Sondergeld P; Sonneveld P; Mateos M-V
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2016;34(15):tps8071
An open-label, dose-escalation phase lb study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO).
Nahi H; Hellemans P; Masterson TJ; Clemens PL; Ahmadi T; San Miguel J; Mateos M-V; Usmani SZ
Meeting abstract: VALUE IN HEALTH. 2014;17(7):A617-A618
TREATMENT SEQUENCING SURVIVAL MODEL FOR PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR STEM CELL TRANSPLANTATION (SCT)
Heeg B; Van Agthoven M; van Beurden-Tan C; Liwing J; Mellqvist UH; Plesner T; Logman F; Aschan J; Einsele H; Treur M; Barendse M; Richardson PG; Palumbo A; Nahi H; Sonneveld P
Meeting abstract: VALUE IN HEALTH. 2014;17(7):A617
BORTEZOMIB RE-TREATMENT IN PATIENTS WITH MULTIPLE MYELOMA (MM). A REAL WORLD MEDICAL PRACTICE EXPERIENCE FROM A SWEDISH NATIONAL REGISTRY
Thilakarathne P; Diels J; van Sanden S; Liwing J; Chirita O; Van Agthoven M; Nahi H
Meeting abstract: VALUE IN HEALTH. 2014;17(7):A545-A546
COMPARATIVE REAL WORLD EFFECTIVENESS OF NOVEL AGENTS VERSUS CONVENTIONAL THERAPIES IN MULTIPLE MYELOMA PATIENTS IN SWEDEN
Thilakarathne P; Diels J; van Sanden S; Liwing J; Van Agthoven M; Chirita O; Nahi H
Meeting abstract: JOURNAL OF CLINICAL ONCOLOGY. 2014;32(15):8513
Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM).
Lokhorst HM; Laubach J; Nahi H; Plesner T; Gimsing P; Hansson M; Minnema M; Lassen UN; Krejcik J; Ahmadi T; Lisby S; Basse L; Brun NC; Richardson PG
Review: LEUKEMIA. 2014;28(2):269-277
IMWG consensus on risk stratification in multiple myeloma
Chng WJ; Dispenzieri A; Chim C-S; Fonseca R; Goldschmidt H; Lentzsch S; Munshi N; Palumbo A; Miguel JS; Sonneveld P; Cavo M; Usmani S; Durie BGM; Avet-Loiseau H
Letter: EUROPEAN JOURNAL OF HAEMATOLOGY. 2014;92(5):454-455
Bendamustine in combination with high-dose radiotherapy and thalidomide is effective in treatment of multiple myeloma with central nervous system involvement
Nahi H; Svedmyr E; Lerner R
Meeting abstract: BLOOD. 2013;122(21):1972
Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011
Blimark C; Holmberg E; Juliusson G; Nahi H; Karin F; Turesson I; Ahlberg L; Svensson R; Linder O; Carlsson K; Kristinsson SY
Review: LEUKEMIA. 2013;27(4):780-791
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Fernandez de Larrea C; Kyle RA; Durie BGM; Ludwig H; Usmani S; Vesole DH; Hajek R; San Miguel JF; Sezer O; Sonneveld P; Kumar SK; Mahindra A; Comenzo R; Palumbo A; Mazumber A; Anderson KC; Richardson PG; Badros AZ; Caers J; Cavo M; Leleu X; Dimopoulos MA; Chim CS; Schots R; Noeul A; Fantl D; Mellqvist U-H; Landgren O; Chanan-Khan A; Moreau P; Fonseca R; Merlini G; Lahuerta JJ; Blade J; Orlowski RZ; Shah JJ
Letter: MEDICAL ONCOLOGY. 2013;30(2):569
In search of the molecular consequences of 8p21 deletion in multiple myeloma: commentary on Gmidene et al
Sutlu T; Alici E; Gahrton G; Nahi H
Meeting abstract: BLOOD. 2012;120(21):73
Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study
Plesner T; Lokhorst H; Gimsing P; Nahi H; Lisby S; Richardson PG
Meeting abstract: BLOOD. 2012;120(21):5033
Is Renal Impairment Still a Poor Prognostic Marker in Myeloma Care?: A Population Based Study Including 1542 Patients
Uttervall K; Andreasson J; Liwing J; Nasman P; Aschan J; Nahi H
Meeting abstract: BLOOD. 2012;120(21):2970
Is Multiple Myeloma a Chronic Disease? A Population Based Study Comparing 1843 Patients to a Matched Swedish Population
Nahi H; Liwing J; Aldrin A; Andreasson J; Blimark C; Carlson K; Enestig J; Flogegard M; Forsberg K; Gruber A; Johansson P; Kviele H; Lauri B; Mellqvist U-H; Nasman P; Swedin A; Svensson M; Uttervall K; Aschan J
Editorial comment: MEDICAL ONCOLOGY. 2012;29(2):1231-1236
Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation
Machaczka M; Nahi H; Karbach H; Klimkowska M; Hagglund H
Corrigendum: LEUKEMIA. 2012;26(5):1153
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (vol 26, pg 149, 2012)
Kumar SK; Lee JH; Lahuerta JJ; Morgan G; Richardson PG; Crowley J; Haessler J; Feather J; Hoering A; Moreau P; Leleu X; Hulin C; Klein SK; Sonneveld P; Siegel D; Blade J; Goldschmidt H; Jagannath S; Miguel JS; Orlowski R; Palumbo A; Sezer O; Rajkumar SV; Durie BGM; Nahi H
Review: JOURNAL OF INTERNAL MEDICINE. 2011;269(2):137-147
Clinical impact of chromosomal aberrations in multiple myeloma
Nahi H; Sutlu T; Jansson M; Alici E; Gahrton G
Meeting abstract: CANCER RESEARCH. 2010;70:2757
NT5C2 single nucleotide polymorphisms affects survival and response in de novo AML patients with normal karyotype
Fyrberg A; Lofti K; Paul E; Paul C; Nahi H; Green H
Meeting abstract: BLOOD. 2009;114(22):221
Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial
Mellqvist U-H; Westin J; Gimsing P; Hjertner O; Lenhoff S; Laane E; Remes K; Steingrimsdottir H; Abildgaard N; Ahlberg L; Carlsson K; Dahl IM; Forsberg K; Gedde-Dahl T; Gregersen H; Gruber A; Guldbrandsen N; Haukas E; Linder O; Nahi H; Nesthus I; Toffner-Clausen N; Silvennoinen R; Andersen NF; Turesson I; Waage A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(2):266-268
The prognostic significance of 8p21 deletion in multiple myeloma
Sutlu T; Alici E; Jansson M; Wallblom A; Dilber MS; Gahrton G; Nahi H
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2008;143(5):751-753
Transmission of chronic lymphocytic leukaemia from a blood stem cell sibling donor to the recipient
Nahi H; Jansson M; Sander B; Ljungman P; Hagglund H
Meeting abstract: BLOOD. 2007;110(11):133B
Expression of p14ARF in de novo AML with normal karyotype.: Implication on drug resistance and survival
Paul EO; Deneberg S; Lehmann S; Bengtzen S; Nahi H
Doctoral thesis: 2007
p53 guardian of the genome and target for improved treatment of leukemia
Nahi H
Show more

Employments

Affiliated to Research, Department of Medicine, Huddinge, Karolinska Institutet, 2025-2026

Degrees and Education

Docent, Karolinska Institutet, 2011
Doctor Of Philosophy, Department of Medicine, Huddinge, Karolinska Institutet, 2007

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI